Article · 20 May 2025
OtherPublished 27 Jul 2016
Decitabine in myelodysplastic syndromes
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Decitabine (5-aza-2’-deoxycytidine), a cytosine analog, inhibits DNA methylation and has dual effects on neoplastic cells, including the reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses. Decitabine has promising clinical efficacy in the treatment of myelodysplastic syndromes (a heterogeneous group of bone marrow malignancies), with evidence of target modulation (hypomethylation) and a favorable toxicity profile. Optimal dosing schedules of decitabine in myelodysplastic syndrome are those that maximize hypomethylation (low dose, high dose intensity, multiple cycles). However, the molecular mechanisms of in vivo response to decitabine are still unclear. Combination therapies that augment decitabine’s epigenetic effect, or take advantage of gene activation, will likely improve clinical responses and may extend its use to the treatment of other malignancies.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Practice.
Article · 20 May 2025
Histological effects of doxorubicin and baobab plants on some organs of rat
Article · 28 Mar 2025
Using
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Practice
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Elias Jabbour”
- BylineArticles whose byline prints “Hagop M Kantarjian”
- BylineArticles whose byline prints “Guillermo Garcia-Manero”
- BylineArticles whose byline prints “Jean-Pierre J Issa”
